BofA warns Fed risks policy mistake with early rate cuts
MASON, Ohio - AtriCure , Inc. (NASDAQ: NASDAQ:ATRC), a prominent medical device company specializing in the treatment of atrial fibrillation and related conditions with a market capitalization of $1.53 billion, announced its preliminary financial results for the fourth quarter and the full year of 2024, along with financial guidance for 2025. According to InvestingPro data, the company maintains a strong financial health profile despite current profitability challenges.
The company reported preliminary unaudited revenue for the fourth quarter of 2024 at $124.3 million, marking a 17% increase over the same period in 2023, maintaining its impressive revenue growth trajectory of 17.56% over the last twelve months. This growth was consistent both as reported and on a constant currency basis. U.S. revenue for the quarter was $101.6 million, up by about 14%, while international revenue saw a significant rise of 28% to $22.7 million. The increase was attributed to robust sales of cryoSPHERE® devices for pain management, AtriClip® devices in open chest procedures, and the EnCompass® clamp. The company's strong gross profit margin of 74.79% reflects efficient operations.
For the full year of 2024, AtriCure expects revenue to reach $465.3 million, which also reflects a 17% growth from the previous year. The management anticipates a positive adjusted EBITDA ranging from $26 million to $29 million, and an adjusted loss per share between $0.74 and $0.80 for the year. These figures are based on non-GAAP measures, and the company will provide GAAP reconciliations when it releases audited results for 2024.
Looking ahead, AtriCure has set its 2025 revenue projections between $517 million and $527 million, with an expected adjusted EBITDA of $40 million to $44 million. The company also forecasts modest cash flow generation for the year. Analysts tracked by InvestingPro maintain a strong bullish consensus on the stock, with price targets ranging from $36 to $61 per share. For deeper insights into AtriCure's financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
President and CEO Michael Carrel expressed optimism for 2025, despite pressures on the U.S. Hybrid franchise, and emphasized the company's commitment to growth, innovation, market expansion, and increased profitability. Furthermore, AtriCure will host an Analyst & Investor Day on Wednesday, March 26, 2025, at its headquarters in Mason, Ohio, to discuss its product portfolio and financial goals.
The company's forward-looking statements are based on current estimates and forecasts, and actual results may differ materially. These statements are subject to risks and uncertainties detailed in AtriCure's regulatory filings.
This news article is based on a press release statement from AtriCure, Inc.
In other recent news, Piper Sandler analysts expressed optimism for several healthcare companies, including ATEC, ATRC, and KIDS, ahead of a major investor conference. The analysts anticipate positive fiscal year outlooks and potential upside for consensus numbers for FNA and SIBN. They also expect companies like DXCM, BSX, GKOS, and PRCT to attract investor interest due to their strong growth profiles and profitability improvement.
In other developments, Procept BioRobotics initiated a public offering of common stock valued at $175 million, with BofA Securities, and Morgan Stanley (NYSE:MS) serving as the joint book-running managers. The company reported robust revenue growth of 66% in the third quarter, totaling approximately $58.4 million, largely attributed to their Hydros units. Analyst firms such as Morgan Stanley, Jefferies, and Truist Securities have given various ratings to Procept BioRobotics.
AtriCure Inc. reported an 18% increase in year-over-year revenue for the third quarter of 2024, reaching $116 million. The company raised its full-year revenue guidance to between $459 million and $462 million, representing a 15% to 16% increase from the previous year. AtriCure remains confident in its growth trajectory in both U.S. and international markets, with a positive adjusted EBITDA of nearly $8 million and continued product innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.